Literature DB >> 14965659

An analysis of factors associated with interval as opposed to screen-detected breast cancers, including hormone therapy and mammographic density.

C E B Crane1, C G Luke, J M Rogers, P E Playford, D M Roder.   

Abstract

A comparison of 270 interval breast cancers in South Australian women aged 50 years and over with 628 age-matched screen-detected cases indicated that the former had more advanced stages (P<0.001), higher grades (P<0.001), and more frequently a history of past breast problems (P<0.027). After adjusting for these factors, and presence of a self-reported breast lump at the last screen, using conditional logistic regression, hormone replacement therapy (HRT) exposure in the 6 months prior to this screen had a raised relative odds (95% CL) of an interval cancer of 1.48 (1.02, 2.14). For 479 women where breast density was measured, high density showed an elevated relative odds of an interval cancer of 2.62 (1.71, 4.02). The relative odds of a high density was raised to 2.02 (1.33, 3.06) when the HRT history was positive. Screeners should be aware when there is a history of HRT or past breast problems, or a high breast density, that there is an increased probability of a subsequent interval cancer.

Entities:  

Year:  2002        PMID: 14965659     DOI: 10.1054/brst.2001.0371

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  8 in total

Review 1.  A review of the influence of mammographic density on breast cancer clinical and pathological phenotype.

Authors:  Michael S Shawky; Cecilia W Huo; Kara Britt; Erik W Thompson; Michael A Henderson; Andrew Redfern
Journal:  Breast Cancer Res Treat       Date:  2019-06-08       Impact factor: 4.872

2.  Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter?

Authors:  Jan T Lowery; Tim Byers; John Kittelson; John E Hokanson; Judy Mouchawar; John Lewin; Dan Merrick; Lisa Hines; Meenakshi Singh
Journal:  Breast Cancer Res Treat       Date:  2011-03-24       Impact factor: 4.872

3.  Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study.

Authors:  Emily Banks; Gillian Reeves; Valerie Beral; Diana Bull; Barbara Crossley; Moya Simmonds; Elizabeth Hilton; Stephen Bailey; Nigel Barrett; Peter Briers; Ruth English; Alan Jackson; Elizabeth Kutt; Janet Lavelle; Linda Rockall; Matthew G Wallis; Mary Wilson; Julietta Patnick
Journal:  BMJ       Date:  2004-08-28

4.  Breast Cancer Screening in Asian Women with Dense Breast by Mammography: A Cross-Sectional Observational Study.

Authors:  Jung Sun Lee; Minkyung Oh
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

5.  The effect of volumetric breast density on the risk of screen-detected and interval breast cancers: a cohort study.

Authors:  Johanna O P Wanders; Katharina Holland; Nico Karssemeijer; Petra H M Peeters; Wouter B Veldhuis; Ritse M Mann; Carla H van Gils
Journal:  Breast Cancer Res       Date:  2017-06-05       Impact factor: 6.466

6.  Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.

Authors:  Veronica L Irvin; Zhenzhen Zhang; Michael S Simon; Rowan T Chlebowski; Shiuh-Wen Luoh; Aladdin H Shadyab; Jessica L Krok-Schoen; Fred K Tabung; Lihong Qi; Marcia L Stefanick; Pepper Schedin; Sonali Jindal
Journal:  JAMA Netw Open       Date:  2020-06-01

7.  Mammographic density and risk of breast cancer by mode of detection and tumor size: a case-control study.

Authors:  Kavitha Krishnan; Laura Baglietto; Carmel Apicella; Jennifer Stone; Melissa C Southey; Dallas R English; Graham G Giles; John L Hopper
Journal:  Breast Cancer Res       Date:  2016-06-18       Impact factor: 6.466

8.  Breast density and breast cancer-specific survival by detection mode.

Authors:  Daniëlle van der Waal; André L M Verbeek; Mireille J M Broeders
Journal:  BMC Cancer       Date:  2018-04-05       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.